


Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

Amendments to the Claims:

Please cancel Claims 25 and 27 without prejudice or disclaimer, amend Claims 1, 23 and 29, and add new Claims 32-37 as set forth below.

1. (Currently amended) A compound of the formula (I):



wherein:

V is selected from CH_2 and NH, and W is NR^1 ; or V is NR^1 , and W is selected from CH_2 and NH;


X is selected from CH_2 and CHOH in the R or S-configuration;

Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH and NR^1 then Y is hydrogen;

Z is selected from hydrogen, halogen, hydroxy, SQ , OQ and Q, where Q is an alkyl, aralkyl or aryl group, ~~where the aryl group is optionally substituted~~;

R^1 is a radical of the formula (II)

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005



A is selected from CH and CR, where R is selected from halogen, alkyl, aralkyl or aryl, OH, NH₂, NHR³, NR³R⁴ and SR⁵, where R³, R⁴ and R⁵ are each alkyl, aralkyl or aryl groups;

B is selected from OH, NH₂, NHR⁶, SH, hydrogen and halogen, where R⁶ is an alkyl, aralkyl or aryl group;

D is selected from OH, NH₂, NHR⁷, hydrogen, halogen and SCH₃, where R⁷ is an alkyl, aralkyl or aryl group;

E is N;

G is selected from CH₂ and NH, or G is absent, provided that where W is NR¹ and G is NH then V is CH₂, and provided that where V is NR¹ and G is NH then W is CH₂,

or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

2. (Previously presented) A compound as claimed in claim 1, where Z is selected from hydrogen, halogen, hydroxy, SQ and OQ.

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

3. (Previously presented) A compound as claimed in claim 1, where V is CH_2 .
4. (Previously presented) A compound as claimed in claim 1, where X is CH_2 .
5. (Previously presented) A compound as claimed in claim 1, where G is CH_2 .
6. (Previously presented) A compound as claimed in claim 1, where Z is OH.
7. (Previously presented) A compound as claimed in claim 1, where Z is SQ.
8. (Previously presented) A compound as claimed in claim 1, where Z is Q.
9. (Previously presented) A compound as claimed in claim 1, where W is NR^1 .
10. (Canceled)
11. (Previously presented) A compound as claimed in claim 1, where W is selected from NH and NR^1 and X is CH_2 .
12. (Previously presented) A compound as claimed in claim 1, where V, X and G are all CH_2 , Z is OH and W is NR^1 .
13. (Previously presented) A compound as claimed in claim 1, where V, X and G are all CH_2 , Z is SQ and W is NR^1 .

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

14. (Previously presented) A compound as claimed in claim 1, where Y is hydrogen.

15. (Previously presented) A compound as claimed in claim 1, where Y is hydroxy.

16. (Previously presented) A compound as claimed in claim 1, where B is hydroxy.

17. (Previously presented) A compound as claimed in claim 1, where B is NH₂.

18. (Previously presented) A compound as claimed in claim 1, where A is CH.

19. (Canceled)

?

20. (Previously presented) A compound as claimed in claim 1, where D is H.

21. (Previously presented) A compound as claimed in claim 1, where D is NH₂.

22. (Canceled)

23. (Currently amended) A compound selected from the group consisting of:
~~as claimed in claim 1, which is:~~

(3R,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4R)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine;

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

(3S,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3,4-dihydroxy-4-methylthiomethyl pyrrolidine;

(3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl) pyrrolidine;

N-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;

N-(9-deazahypoxanthin-9-yl)methyl-1,4-dideoxy-1,4-imino-D-ribitol;

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;

(3R,4S)-1[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;

(3R,4R)-1-[(9-deazaguanin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4-chlorophenylthiomethyl) pyrrolidine;

(3R,4R)-1-[(6-chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl) pyrrolidine;

(3R,4R)-1-[(6-azido-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl) pyrrolidine; ~~or~~ and


(3R,4R)-1-[(9-deezaadenin-9-yl)methyl]-3-acetoxy-4-(acetoxymethyl)pyrrolidine; or a pharmaceutically acceptable salt thereof.

24. (Previously presented) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in claim 1 and a carrier.

25-28. (Canceled)

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

29. (Previously presented) ~~A~~ The compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof.

30. (Previously presented) The compound of claim 1, wherein the salt is derived from an acid selected from the group consisting of hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, lactic acid, fumaric acid, succinic acid, tartaric acid, gluconic acid, citric acid, methanesulfonic acid and p-toluenesulfonic acid.

31. (Previously presented) The compound of claim 29, wherein the salt is a hydrochloride salt.

32. (New) The compound of claim 23, wherein the salt is derived from an acid selected from the group consisting of hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, lactic acid, fumaric acid, succinic acid, tartaric acid, gluconic acid, citric acid, methanesulfonic acid and p-toluenesulfonic acid.

Applicants: Gary Brian Evans, et al.
Appl. No.: 10/524,995
Filing Date: September 27, 2005

33. (New) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in claim 23 and a carrier.

34. (New) The compound of claim 29, wherein the salt is derived from an acid selected from the group consisting of hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, lactic acid, fumaric acid, succinic acid, tartaric acid, gluconic acid, citric acid, methanesulfonic acid and p-toluenesulfonic acid.

35. (New) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound as claimed in claim 29 and a carrier.

36. (New) The compound of claim 1, wherein the salt is a hydrochloride salt.

37. (New) The compound of claim 23, wherein the salt is a hydrochloride salt.